Genomic Vision strengthens team
Appoints chief finance officer and vice president of research and development
Prior to joining Genomic Vision, Martin was cfo at Cytomics Pharmaceuticals (2003–2008), a biopharmaceutical company he co-founded with Dominique Thomas (Research Director at the CNRS Centre for Molecular Genetics, Gif-sur-Yvette) and for which he led the first rounds of financing. Prior to this he worked for 10 years as a consultant for Syndex, an auditing firm.
Conseiller joined Genomic Vision in 2009 after working for more than 17 years as a senior manager at sanofi-aventis (primarily within the oncology division). He is a pioneer in the application of functional genomics to drug discovery (from drug target screening to clinical trials) and has designed and led several projects for drug screening (small molecules and gene therapy) in the fields of tumour suppression, DNA replication and tumour metabolism. He holds a PhD from Pierre and Marie Curie University, Paris. In 1997, he won the Rhone-Poulenc Rorer Research Prize for his work on the development of chimeric tumour suppressors for gene therapy of cancer.
You may also like
Research & Development
CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration
Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Research & Development
New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research
Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
Research & Development
Chemify secures $1.6m Gates Foundation grant to accelerate digital chemistry for tuberculosis drug discovery
The follow-on funding supports Chemify and Lgenia in designing and synthesising new small-molecule candidates for high-priority TB targets using Chemify’s AI-driven digital chemistry platform
Research & Development
PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific
The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape